June 2 (Bloomberg) — Amgen Inc.’s bone-strengthening injection denosumab, for postmenopausal women with osteoporosis, will be the first biotechnology drug likely to be prescribed by patients’ primary physicians rather than specialists. Shares rose today the most in about 11 months.
Tag Archive for 'amgen-inc'
Amgen Drug Becomes First Biologic for Primary Care (Update3)
Published June 2nd, 2010 in Osteosarcoma News. 0 CommentsAmgen’s Bone Drug Enters Competitive U.S. Osteoporosis Market
Published June 2nd, 2010 in Osteosarcoma News. 0 CommentsAmgen Inc.’s bone-strengthening injection denosumab for postmenopausal women with osteoporosis will be the first biotechnology drug likely to be prescribed by patients’ primary physicians not specialists.
Sooner-than-Expected FDA Nod for Amgen’s Bone Drug Prolia
Published June 2nd, 2010 in Osteosarcoma News. 0 CommentsNearly two months ahead of its July 25 PDUFA date, Amgen Inc.’s Prolia (denosumab) gained FDA approval in postmenopausal women with osteoporosis who are at high risk for fractures, and that earlier-than-expected win could bode well as the Thousand Oaks, Calif.-based firm seeks to expand denosumab in other indications.
Amgen’s Bone Drug Cleared by U.S. for Osteoporosis (Update2)
Published June 2nd, 2010 in Osteosarcoma News. 0 CommentsJune 1 (Bloomberg) — Amgen Inc.’s bone-strengthening drug denosumab, the focus of the largest development program in the company’s history, was cleared by U.S. regulators for use in postmenopausal women with osteoporosis.
Amgen’s Bone Drug Cleared by U.S. for Osteoporosis (Update1)
Published June 1st, 2010 in Osteosarcoma News. 0 CommentsAmgen Inc.’s bone-strengthening drug denosumab, the focus of the largest development program in the company’s history, was cleared by U.S. regulators for use in older women with osteoporosis.
Recent Comments